T1	Outcomes 508 564	effect of administration time and fat or caloric content
T2	Outcomes 737 767	the pharmacokinetic properties
T3	Outcomes 923 950	the safety and tolerability
T4	Outcomes 1058 1105	the pharmacokinetic properties of pregabalin CR
T5	Outcomes 1324 1332	evening.
T6	Outcomes 1333 1346	Blood samples
T7	Outcomes 1374 1384	post-dose.
T8	Outcomes 1385 1411	Pharmacokinetic parameters
T9	Outcomes 1427 1462	from plasma concentration-time data
T10	Outcomes 1647 1658	pregabalin.
T11	Outcomes 1659 1693	Peak plasma concentrations (C max)
T12	Outcomes 1853 1877	evening, total exposures
T13	Outcomes 2147 2156	breakfast
T14	Outcomes 2195 2205	CR and IR.
T15	Outcomes 2206 2220	Bioequivalence
T16	Outcomes 2476 2482	fasted
T17	Outcomes 2604 2616	Additionally
T18	Outcomes 2794 2819	pregabalin CR and IR were
T19	Outcomes 2838 2876	all studies, with no serious or severe
T20	Outcomes 2982 3011	accompanying meal had minimal
